Gary S. Goldberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gary S. Goldberg has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Yongquan Shen
The ¶Department of Physiology and Biophysics, Stony Brook University, Stony Brook, New York 11794-8661
3 shared publicationsHarini Krishnan
Graduate School of Biomedical Sciences and Department of Molecular Biology, School of Osteopathic Medicine, University of Medicine and Dentistry of New Jersey, Stratford, New Jersey 08084, USA
2 shared publicationsChen-Shan Chen
1 shared publicationDean E. McNulty
Proteomics and Biological Mass Spectrometry, Molecular Discovery Research, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
1 shared publicationDmitry Temiakov
Graduate School of Biomedical Sciences, University of Medicine and Dentistry of New Jersey, Stratford, New Jersey, United States of America
1 shared publicationEvan Nevel
The ¶Department of Physiology and Biophysics, Stony Brook University, Stony Brook, New York 11794-8661
1 shared publication
Latest Publications
- Open Access
- 1 April 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (17) , 12215-12221
Serines in the Intracellular Tail of Podoplanin (PDPN) Regulate Cell Motility
- 1 April 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (17) , 12215-12221
Open AccessSerines in the Intracellular Tail of Podoplanin (PDPN) Regulate Cell Motility
- Open Access
- 23 July 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (7) , e41845
Plant Lectin Can Target Receptors Containing Sialic Acid, Exemplified by Podoplanin, to Inhibit Transformed Cell Growth and Migration
Cancer is a leading cause of death of men and women worldwide. Tumor cell motility contributes to metastatic invasion that causes the vast majority of cancer deaths. Extracellular receptors modified by α2,3-sialic acids that promote this motility can serve as ideal chemotherapeutic targets. For example, the extracellular domain of the mucin receptor podoplanin (PDPN) is highly O-glycosylated with α2,3-sialic acid linked to galactose. PDPN is activated by endogenous ligands to induce tumor cell motility and metastasis. Dietary lectins that target proteins containing α2,3-sialic acid inhibit tumor cell growth. However, anti-cancer lectins that have been examined thus far target receptors that have not been identified. We report here that a lectin from the seeds of Maackia amurensis (MASL) with affinity for O-linked carbohydrate chains containing sialic acid targets PDPN to inhibit transformed cell growth and motility at nanomolar concentrations. Interestingly, the biological activity of this lectin survives gastrointestinal proteolysis and enters the cardiovascular system to inhibit melanoma cell growth, migration, and tumorigenesis. These studies demonstrate how lectins may be used to help develop dietary agents that target specific receptors to combat malignant cell growth.
- 23 July 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (7) , e41845
Open AccessPlant Lectin Can Target Receptors Containing Sialic Acid, Exemplified by Podoplanin, to Inhibit Transformed Cell Growth and Migration
Cancer is a leading cause of death of men and women worldwide. Tumor cell motility contributes to metastatic invasion that causes the vast majority of cancer deaths. Extracellular receptors modified by α2,3-sialic acids that promote this motility can serve as ideal chemotherapeutic targets. For example, the extracellular domain of the mucin receptor podoplanin (PDPN) is highly O-glycosylated with α2,3-sialic acid linked to galactose. PDPN is activated by endogenous ligands to induce tumor cell motility and metastasis. Dietary lectins that target proteins containing α2,3-sialic acid inhibit tumor cell growth. However, anti-cancer lectins that have been examined thus far target receptors that have not been identified. We report here that a lectin from the seeds of Maackia amurensis (MASL) with affinity for O-linked carbohydrate chains containing sialic acid targets PDPN to inhibit transformed cell growth and motility at nanomolar concentrations. Interestingly, the biological activity of this lectin survives gastrointestinal proteolysis and enters the cardiovascular system to inhibit melanoma cell growth, migration, and tumorigenesis. These studies demonstrate how lectins may be used to help develop dietary agents that target specific receptors to combat malignant cell growth.
- 1 May 2012
- Published by SAGE Publications in Genes & Cancer
- Vol. 3 (5-6) , 426-435
Src Points the Way to Biomarkers and Chemotherapeutic Targets
The role of Src in tumorigenesis has been extensively studied since the work of Peyton Rous over a hundred years ago. Src is a non-receptor tyrosine kinase that plays key roles in signaling pathways controlling tumor cell growth and migration. Src regulates the activities of numerous molecules to induce cell transformation. However, transformed cells do not always migrate and realize their tumorigenic potential. They can be normalized by surrounding nontransformed cells by a process called contact normalization. Tumor cells need to override contact normalization to become malignant or metastatic. In this review, we discuss the role of Src in cell migration and contact normalization, with emphasis on Cas and Abl pathways. This paradigm illuminates several chemotherapeutic targets and may lead to the identification of new biomarkers and the development of effective anticancer treatments.
- 1 May 2012
- Published by SAGE Publications in Genes & Cancer
- Vol. 3 (5-6) , 426-435
Src Points the Way to Biomarkers and Chemotherapeutic Targets
The role of Src in tumorigenesis has been extensively studied since the work of Peyton Rous over a hundred years ago. Src is a non-receptor tyrosine kinase that plays key roles in signaling pathways controlling tumor cell growth and migration. Src regulates the activities of numerous molecules to induce cell transformation. However, transformed cells do not always migrate and realize their tumorigenic potential. They can be normalized by surrounding nontransformed cells by a process called contact normalization. Tumor cells need to override contact normalization to become malignant or metastatic. In this review, we discuss the role of Src in cell migration and contact normalization, with emphasis on Cas and Abl pathways. This paradigm illuminates several chemotherapeutic targets and may lead to the identification of new biomarkers and the development of effective anticancer treatments.
- Open Access
- 1 March 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (13) , 9649-9656
Src Induces Podoplanin Expression to Promote Cell Migration
- 1 March 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (13) , 9649-9656
Open AccessSrc Induces Podoplanin Expression to Promote Cell Migration